| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J].CA Cancer J Clim,2011,61(2):69-90.
|
| [2] |
Thun MJ, DeLancey JO, Center MM, et al. The global burden of cancer:priorities for prevention[J].Carcinogenesis,2010,31(1):100-110.
|
| [3] |
Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study[J].Lancet, 1997,349(9061):1269-1276.
|
| [4] |
Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0) [J].J Surg Oncol,2003,84(4):192-197.
|
| [5] |
Ganem G, Tubiana-Hulin M, Fumoleau P, et al. Phase Ⅱtrial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer [J].Ann Oncol,2003,14(11):1623-1628.
|
| [6] |
Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer[J]. Am Surg,2004,70(7):565-569.
|
| [7] |
刘晶晶,张瑾.乳腺癌新辅助化疗研究进展[J/CD].中华乳腺病杂志:电子版,2012,6(1):40-43.
|
| [8] |
凌霄,王冰,骆小敏. 紫杉醇注射液化疗的不良反应分析[J].中国医药指南,2012,10(5):190-191.
|
| [9] |
刘芳,江泽飞,宋三泰,等. 单药紫杉醇治疗晚期乳腺癌剂量强度与疗效和毒性的关系[J]. 中华肿瘤杂志,2005,27(1):56-58.
|
| [10] |
任淑霞,郭臻.单药紫杉醇治疗晚期乳腺癌36 例疗效分析[J].中国误诊学杂志,2009,9(21):5230-5231.
|
| [11] |
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J].Nature,2000,406(6797):747-752.
|
| [12] |
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci U S A,2003,100(14):8418-8423.
|
| [13] |
Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL ( CALGB 150007/150012, ACRIN 6657) [J]. J Clin Oncol,2009,27(18S):515.
|
| [14] |
Jacquemier J, Penault-Llorca F, Mnif H, et al. Identification of a basal-like subtype and comparative effect of epirubicinbased chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA) [J]. J Clin Oncol,2006,24(18S):509.
|
| [15] |
Huober J, von Minckwitz G, Denkert C, et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel,doxorubicin,and cyclophosphamide(TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment [J]. J Clin Oncol,2009,27 (15S):524.
|
| [16] |
Nagai H, Matsui T,Kanayama M,et al. Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma[J].Camcer Chemother Pharmacol,2011,68(1):139-145.
|
| [17] |
Wen J, Shen WL, Yang SH. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis[J]. Hepatobiliary Pancreat Dis Int,2006,5(2):224-227.
|
| [18] |
陈孝平,石应康,邱贵兴,等. 外科学[M].2 版. 北京:人民卫生出版社,2010.
|
| [19] |
Cabibbo G, Palmeri L, Palmeri S, et al. Should cirrhosis change our attitude towards treating non-hepatic cancer? [J].Liver Int,2012,32(1):21-27.
|
| [20] |
Trivin F, Boucher E, Vauléon E, et al. Management of esophageal carcinoma associated with cirrhosis: a retrospective case-control analysis [J].J Oncol,2009,2009:173421.
|
| [21] |
Hsieh PY,Huang SI,Li DK,et al. Primary effusion lymphoma involving both pleural and abdominal cavities in a patient with hepatitis B virus-related liver cirrhosis[J]. J Formos Med Assoc,2007,106(6):504-508.
|